Bellevue Group AG — 13F Holdings & Portfolio

CIK 1674546 · latest 13F-HR filed 2026-08-14

Bellevue Group AG manages $4.75B in 13F-reported U.S. long-equity assets across 164 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AMGN (6.34%), ARGX (5.88%), VRTX (5.83%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions and exited 24; 70 existing positions rose in reported value and 48 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$4.75B

Long-equity book

Holdings
164

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+17 / −24 / ↑70 / ↓48

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 42.9%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Bellevue Group AG Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 AMGEN INC AMGN 031162100 $301.1M 6.34% 831,588 SH
2 ARGENX SE ARGX 04016X101 $279.3M 5.88% 301,000 SH
3 VERTEX PHARMACEUTICALS INC VRTX 92532F100 $276.9M 5.83% 557,375 SH
4 GILEAD SCIENCES INC GILD 375558103 $264.4M 5.56% 2,093,000 SH
5 REVOLUTION MEDICINES INC RVMD 76155X100 $195.2M 4.11% 1,042,424 SH
6 ORUKA THERAPEUTICS INC ORKA 687604108 $157.7M 3.32% 1,657,190 SH
7 INSMED INC INSM 457669307 $147.3M 3.10% 1,381,740 SH
8 SCHOLAR ROCK HLDG CORP SRRK 80706P103 $134.5M 2.83% 2,445,032 SH
9 NUVALENT INC NUVL 670703107 $130.1M 2.74% 1,053,268 SH
10 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $123.4M 2.60% 6,717,515 SH
11 RELAY THERAPEUTICS INC RLAY 75943R102 $115.7M 2.43% 6,184,046 SH
12 VAXCYTE INC PCVX 92243G108 $114.4M 2.41% 1,967,377 SH
13 INTUITIVE SURGICAL INC ISRG 46120E602 $101.3M 2.13% 254,809 SH
14 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $98.8M 2.08% 182,301 SH
15 CRINETICS PHARMACEUTICALS IN CRNX 22663K107 $98.0M 2.06% 2,620,000 SH
16 REGENERON PHARMACEUTICALS REGN 75886F107 $97.9M 2.06% 157,000 SH
17 IMMUNOCORE HLDGS PLC IMCR 45258D105 $88.5M 1.86% 2,788,245 SH
18 BRIDGEBIO PHARMA INC BBIO 10806X102 $87.2M 1.83% 1,170,130 SH
19 ABBOTT LABORATORIES ABT 002824100 $85.9M 1.81% 947,115 SH
20 STRYKER CORPORATION SYK 863667101 $84.5M 1.78% 268,461 SH
21 MEDTRONIC PLC MDT G5960L103 $77.8M 1.64% 994,233 SH
22 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $75.6M 1.59% 1,490,000 SH
23 IONIS PHARMACEUTICALS INC IONS 462222100 $74.9M 1.58% 944,577 SH
24 VERA THERAPEUTICS INC VERA 92337R101 $72.6M 1.53% 1,692,906 SH
25 JADE BIOSCIENCES INC JBIO 008064206 $67.9M 1.43% 3,057,996 SH
26 EDWARDS LIFESCIENCES CORP EW 28176E108 $66.9M 1.41% 739,234 SH
27 ULTRAGENYX PHARMACEUTICAL IN RARE 90400D108 $66.2M 1.39% 1,982,775 SH
28 UNITEDHEALTH GROUP INC UNH 91324P102 $62.0M 1.30% 149,127 SH
29 DEXCOM INC DXCM 252131107 $55.4M 1.17% 822,489 SH
30 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $44.7M 0.94% 1,200,000 SH
31 AVALYN PHARMACEUTICALS INC AVLN 05348Y105 $44.4M 0.94% 1,350,000 SH
32 DAMORA THERAPEUTICS INC DMRA 36322Q206 $42.1M 0.89% 1,618,846 SH
33 DISC MEDICINE INC IRON 254604101 $41.0M 0.86% 560,000 SH
34 THERMO FISHER SCIENTIFIC INC TMO 883556102 $40.0M 0.84% 79,816 SH
35 BOSTON SCIENTIFIC CORP BSX 101137107 $37.9M 0.80% 887,650 SH
36 ELI LILLY & CO LLY 532457108 $35.8M 0.75% 29,882 SH
37 CG ONCOLOGY INC CGON 156944100 $35.1M 0.74% 493,596 SH
38 IDEXX LABS INC IDXX 45168D104 $32.5M 0.68% 61,780 SH
39 RESMED INC RMD 761152107 $28.9M 0.61% 148,195 SH
40 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $28.8M 0.61% 1,190,000 SH
41 KRYSTAL BIOTECH INC KRYS 501147102 $28.2M 0.59% 76,000 SH
42 DANAHER CORP DEL DHR 235851102 $27.4M 0.58% 143,844 SH
43 JOHNSON & JOHNSON JNJ 478160104 $26.2M 0.55% 103,280 SH
44 SEAPORT THERAPEUTICS INC SPTX 81221K108 $23.9M 0.50% 1,100,000 SH
45 PALVELLA THERAPEUTICS INC NE PVLA 697947109 $23.7M 0.50% 155,000 SH
46 ALIGN TECHNOLOGY INC ALGN 016255101 $23.6M 0.50% 139,680 SH
47 ANNEXON INC ANNX 03589W102 $23.4M 0.49% 4,100,016 SH
48 HUMANA INC HUM 444859102 $23.2M 0.49% 58,398 SH
49 ELEVANCE HEALTH INC FORMERLY ELV 036752103 $21.8M 0.46% 56,449 SH
50 TANGO THERAPEUTICS INC TNGX 87583X109 $21.7M 0.46% 694,182 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $4.75B 164 0001104659-26-096739
2026-03-31 2026-05-15 $4.20B 167 0001104659-26-061375
2025-12-31 2026-02-17 $5.28B 213 0001104659-26-016360
2025-09-30 2025-11-14 $4.81B 186 0001104659-25-112697
Filer Information
Address
THEATERSTRASSE 12
ZURICH CH-8001
Phone
41 44 267 67 77
Filing Manager
Bellevue Group AG
ZURICH, V8
Signatory
Christoph Eisenring / Stefano Montalbano
Head Legal & Compliance / CFO